Ipsen S.A. (OTCMKTS:IPSEY) Increases Dividend to $0.29 Per Share

Ipsen S.A. (OTCMKTS:IPSEY - Get Free Report) announced a dividend on Tuesday, June 3rd, investing.com reports. Shareholders of record on Tuesday, June 10th will be paid a dividend of 0.2896 per share on Wednesday, June 25th. This represents a yield of 0.97%. The ex-dividend date of this dividend is Monday, June 9th. This is a 23.9% increase from Ipsen's previous dividend of $0.23.

Ipsen Trading Up 3.2%

Shares of IPSEY stock traded up $0.95 during trading hours on Wednesday, hitting $30.45. 496 shares of the company were exchanged, compared to its average volume of 4,872. Ipsen has a 52-week low of $25.11 and a 52-week high of $33.97. The firm has a fifty day simple moving average of $28.41 and a 200 day simple moving average of $29.15.

Analysts Set New Price Targets

Separately, Deutsche Bank Aktiengesellschaft reaffirmed a "buy" rating on shares of Ipsen in a research report on Wednesday, April 2nd.

About Ipsen

Ipsen SA operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial.